Altogether the basic materials sector seems to be predominantly mature in terms of its industry life cycle. Companies appear to be vastly competitive and consolidation seems to be a natural trend.

Various symptoms indicate chronic myelogenous leukemia (CML) has progressed from one phase to another. These include an increase in leukemia cells, a change in a person’s platelet count, and worsening ...

Several less well-known disorders share some characteristics with CML. These rare CML-like disorders are distinct entities that require specific diagnostic and treatment considerations. Atypical CML, ...

—Tyrosine kinase inhibitors have revolutionized treatment for patients suffering from chronic myeloid leukemia, but cost—and cost-sharing—can be a factor in determining who has access to these ...

Medications for CML directly destroy cancer cells or help the body’s immune system attack cancer cells to prevent them from growing. Medications may not cure CML, so people may need to continue taking ...

Doctors use molecular responses to monitor the effectiveness of CML treatment. A major molecular response is when the amount of the abnormal BCR–ABL gene in your blood and bone marrow is lowered to ...

To evaluate the role of Hh signalling in CML, Reya and colleagues developed mice that lacked expression of smoothened (SMO), the transmembrane protein that transmits Hh signals, in haematopoietic ...

Chronic myelogenous leukemia (CML) is a cancer that affects your blood cells and bone marrow -- the soft part inside your bones where blood cells are made. You may also hear your doctor call it ...

Two posters presented at the European Hematology Association 2021 Virtual Congress evaluated tyrosine kinase inhibitor (TKI) selection in the front line and compared first-generation to ...